Novo Nordisk has launched its Wegovy weight-loss pill in the US, sparking a new price war. The once-daily pill is the first GLP-1 tablet on the market and costs far less than injectable alternatives. Self-paying patients can access starter doses for $149 a month, with insured patients paying from $25. The company aims to regain market share lost to rivals such as Eli Lilly, whose injectable drugs dominate the sector. The pill is now available through major US pharmacies and telehealth providers, with wider rollout planned. Novo hopes the needle-free option will attract new patients and revive growth after a difficult year.
Trending
- Secular Iran: How a Post-Theocratic State Could Shift Global Power
- Western Euthanasia Expansion: The Ethical Crisis Deepens
- Spain’s Euthanasia-Immigration Storm: Noelia Castillo Ramos Case
- Southern Africa’s Quiet Turn Westward: Economic Shift Drives New Alliances
- California Honors Genentech 50-Year Legacy
- UConn Wins NCAA Final Four Thriller
- New U.S. Sustainability Rules Guide Firms
- Senate Advances DHS Funding Package
Novo Nordisk Launches Wegovy Weight-Loss Pill in US, Intensifying Price Competition
Andrew Rogers
Andrew Rogers is a freelance journalist based in Chicago, USA, with over 10 years of experience covering Politics, World Affairs, Business, Health, Technology, Finance, Lifestyle, and Culture. He graduated with a degree in Journalism from the University of Florida. Over the years, he has contributed to leading outlets such as The New York Times, CNN, and Reuters. Recognized for his sharp reporting and thoughtful analysis, Andrew delivers accurate and timely news that keeps readers updated on key national and global developments.
Add A Comment